Assessing the risk of dupilumab use for atopic dermatitis during the COVID-19 pandemic - 19/08/20
Doi : 10.1016/j.jaad.2020.06.015
Donovan G. Kearns, BA a, Shelley Uppal, PhD b, Vipawee S. Chat, BS c, Jashin J. Wu, MD d, ⁎ 
a Loma Linda University School of Medicine, Loma Linda, California
b Albany Medical College School of Medicine, Albany, New York
c Medical College of Georgia at Augusta University, Augusta, Georgia
d Dermatology Research and Education Foundation, Irvine, California
∗Correspondence and reprint requests to: Jashin J. Wu, MD
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Le texte complet de cet article est disponible en PDF.
| Funding sources: None. |
|
| Conflicts of interest: Dr Wu is or has been an investigator, consultant, or speaker for AbbVie, Almirall, Amgen, Arcutis, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Dermavant, Dermira, Dr. Reddy's Laboratories, Eli Lilly, Janssen, LEO Pharma, Novartis, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, UCB, and Valeant Pharmaceuticals North America LLC. Authors Kearns, Uppal, and Chat have no conflicts of interest to disclose. |
|
| IRB approval status: Not applicable. |
© 2020
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 83 - N° 3
P. e251-e252 - septembre 2020 Retour au numéro
Article précédent
- Could antiphospholipid antibodies contribute to coagulopathy in COVID-19?
- Aurora Parodi, Giulia Gasparini, Emanuele Cozzani
- Reply to “Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients”: To consider varicella-like exanthem associated with COVID-19, virus varicella zoster and virus herpes simplex must be ruled out
- Mar Llamas-Velasco, Pedro Rodríguez-Jiménez, Pablo Chicharro, Diego De Argila, Patricia Muñoz-Hernández, Esteban Daudén
Bienvenue sur EM-consulte, la référence des professionnels de santé.